DNL151 is currently being tested in late-stage clinical studies in both LRRK2-PD and sporadic PD patients, and the question of whether LRRK2 kinase inhibition can rescue PD-relevant defects in lysosomal homeostasis and modify disease progression in these patient populations will ultimately be resolved in the clinic. Here, LRRK2 is linked to Parkinson disease.